WU-KONG28 Trial

Abstract LBA8500 X Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28). Snangnai, China Background: Sunvozertinib has been granted accelerated approval in the US and China for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor exon 20 insertion mutations (EGFR exon20ins) who failed platinum-based chemotherapy, based on results from two phase 2 single arm pivotal studies (WU-KONG1B [NCT03974022] and WU- KONG6 [NCT05712902]). WU-KONG28 (NCT05668988) is a multinational randomized confirmatory phase 3 study to compare sunvozertinib versus platinum-based chemotherapy as first-line treatment in advanced NSCLC patients with EGFR exon20ins. Here we reported the primary analysis of WU-KONG28 study results. --- Methods: Eligible patients were randomized in a 1:1 ratio, stratified by baseline brain metastasis status, to receive either sunvozertinib 300 mg once daily or chemotherapy (carboplatin [AUC5] and pemetrexed [500 mg/m²]) once every 3 weeks for up to 6 cycles, followed by pemetrexed maintenance therapy until disease progression or other discontinuation criteria were met. Patients in the chemotherapy arm could cross over to receive sunvozertinib upon confirmed progressive disease by the blinded independent central review (BICR). The primary endpoint was progression free survival (PFS) assessed by BICR per RECIST 1.1. Secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DoR), and safety profile. PFS and os were analyzed using log-rank test and Cox proportional hazards model. The data cutoff date was Jan 16, 2026. --- Results: A total of 324 patients were randomized to receive sunvozertinib (N=163) or chemotherapy (N=161). Baseline characteristics were generally balanced between the two arms. PFS by BICR was significantly longer with sunvozertinib than chemotherapy (median: 10.3 vs 7.5 months; hazard ratio [HR]: 0.65, 95% confidence interval [CI]: 0.50, 0.85, p=0.0008). The PFS benefit was consistent in trends across subgroups. In the chemotherapy arm, 90.2% of patients with BICR-confirmed disease progression crossed over to receive sunvozertinib. The os data were immature. Patients in the sunvozertinib arm showed higher confirmed ORR (58.9% vs 31.1%) and longer median DoR (11.2 vs 7.1 months). Safety profile of sunvozertinib was similar to what was previously reported. Drug-related treatment emergent adverse events (TEAEs) leading to treatment discontinuation occurred in 7.4% of patients. No drug-related TEAE leading to fatal outcome was reported. --- Conclusion: Sunvozertinib demonstrated significantly superior antitumor efficacy than chemotherapy with a manageable safety profile. These results support sunvozertinib as a first-line treatment for advanced NSCLC harboring EGFR exon20ins.

The NEW ENGLAND JOURNAL of MEDICINE ORIGINAL ARTICLE f X in x First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations Authors: Caicun Zhou, M.D., Ph.D., Laurent Greillier, M.D., Ph.D., Geoffrey Liu, M.D., Thomas John, M.B., B.S., Ph.D., Ligang Xing, M.D., Ph.D., Dariusz Kowalski, M.D., Ph.D., Regan M. Memmott, M.D., Ph.D., +23 , for the WU-KONG28 Investigators* Author Info & Affiliations Published May 29, 2026 --- 100 Median 90 Progression-free Survival 80 (95% CI) 70 mo Percentage of Patients 60 Sunvozertinib 10.3 (8.3-14.0) Chemotherapy 7.5 (6.7-8.5) 50 46.1 Hazard ratio for disease 40 33.2 progression or death, 30 0.65 (95% CI, 0.50-0.85) Sunvozertinib P<0.001 20 26.7 Chemotherapy 10 17.1 0 0 3 6 9 12 15 18 21 24 27 30 33 Months since Randomization No. at Risk Sunvozertinib 163 143 108 74 60 48 34 26 18 9 3 0 Chemotherapy 161 128 84 51 28 22 14 7 6 2 1 0 --- Progressive Stable Partial Not evaluable disease disease response A Best Change in Tumor Size in the Sunvozertinib Group 100 80 60 Percentage Change from Baseline 40 20 0 -20 -40 -60 -80 -100 Patients B Best Change in Tumor Size in the Chemotherapy Group 100 80 60 Percentage Change from Baseline 40 20 0 -20 -40 -60 -80 -100 Patients C Duration of Response 100 80 Percentage of Patients with Response 60 40 Sunvozertinib 20 Chemotherapy 0 0 3 6 9 12 15 18 21 24 27 30 33 Months since Randomization No. at Risk Sunvozertinib 96 91 64 48 36 28 22 17 9 4 2 0 Chemotherapy 50 44 29 13 9 5 1 1 1 0 0 0

MEDICINE OF 1926 1812 NEW NOR ENGLAND The NEW ENGLAND JOURNAL JOURNAL of MEDICINE ORIGINAL ARTICLE f X in x First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations Authors: Caicun Zhou, M.D., Ph.D., Laurent Greillier, M.D., Ph.D., Geoffrey Liu, M.D., Thomas John, M.B., B.S., Ph.D., Ligang Xing, M.D., Ph.D., Dariusz Kowalski, M.D., Ph.D., Regan M. Memmott, M.D., Ph.D., +23 , for the WU-KONG28 Investigators* Author Info & Affiliations Published May 29, 2026

100 Median 90 Progression-free Survival 80 (95% CI) 70 mo Percentage of Patients 60 Sunvozertinib 10.3 (8.3-14.0) Chemotherapy 7.5 (6.7-8.5) 50 46.1 Hazard ratio for disease 40 33.2 progression or death, 30 0.65 (95% CI, 0.50-0.85) Sunvozertinib P<0.001 20 26.7 Chemotherapy 10 17.1 0 0 3 6 9 12 15 18 21 24 27 30 33 Months since Randomization No. at Risk Sunvozertinib 163 143 108 74 60 48 34 26 18 9 3 0 Chemotherapy 161 128 84 51 28 22 14 7 6 2 1 0 --- Table 2. Key Efficacy End Points.* Sunvozertinib Chemotherapy Treatment Effect End Point (N=163) (N=161) (95% CI)T P Value Progression-free survival Median (95% CI) - mo 10.3 (8.3-14.0) 7.5 (6.7-8.5) 0.65 (0.50-0.85) <0.001 Percentage of patients (95% CI) At 12 mo 46.1 (37.9-53.9) 26.7 (19.3-34.6) NA NA At 18 mo 33.2 (25.3-41.3) 17.1 (10.7-24.7) NA NA At 24 mo 23.0 (15.8-31.0) 10.3 (5.1-17.6) NA NA Objective response:- Percentage of patients (95% CI) 58.9 (50.9-66.5) 31.1 (24.0-38.8) 3.2 (2.0-5.0) NA Duration of response Median (95% CI) - mo 11.2 (8.2-13.9) 7.1 (6.9-11.1) NA NA Overall survival Median (95% CI) — mo 29.8 (21.8-NE) 28.8 (20.7-NE) 0.99 (0.70-1.40) 0.48 Percentage of patients (95% CI) At 18 mo 65.5 (56.9-72.9) 67.2 (58.4-74.5) NA NA At 24 mo 57.4 (48.3-65.4) 56.2 (46.9-64.5) NA NA At 30 mo 50.0 (39.4-59.6) 49.1 (39.4-58.1) NA NA * The efficacy population included all the patients who had undergone randomization. NA denotes not applicable, and NE could not be estimated. t The treatment effect is shown as a hazard ratio for progression-free survival and overall survival and as an odds ratio for objective response. # Progression-free survival and objective response were assessed by blinded independent central review. --- Drug Sponsor Study ID Treatment regimen Enrollment Primary Status endpoint Scope Furmonertinib 240 mg (oral) FURVENT / Furmonertinib R Recruitment Allist NCT05607550 N=375 Furmonertinib 160 mg (oral) 375 PFS 1:1:1 completed International Platinum-based chemotherapy (IV) WU-KONG 28 / Sunvozertinib (oral) Dizal R Primary readout Sunvozertinib N=320 320 PFS NCT05668988 International 1:1 expected in 2026 Platinum-based chemotherapy (IV) PLB1004 (oral) Andamertinib Avistone NCT06281964 N=327 R 327 PFS Active, recruiting China only (PLB1004) 1:1 Platinum-based chemotherapy (IV) ± sintilimab (IV) Zipalertinib (oral) + Taiho / R Platinum-based chemotherapy (IV) Zipalertinib NCT05973773 N=260 260 PFS Active, recruiting International Cullinan 1:1 Chemotherapy (IV) YK-029A (oral) Suzhou CTR20230490/ R N=350 350 PFS YK-029A Recruiting China only Puhe NCT05767892 1:1 Platinum-based chemotherapy (IV) JMT101 (oral) + osimertinib (oral) Shanghai CTR20241252/ R JMT101 N=398 398 PFS Active, recruiting China only JMT-Bio NCT06380348 1:1 Cisplatin (IV) + pemetrexed (IV) Experimental arm Control arm IV: Intravenous PFS: Progression-free survival R Randomization --- Sequential treatment in the future? Chemotherapy + Amivantamab EGFR ex20ins TKI ADC +/- EGFR ex20ins TKI EGFR ex20ins TKI Chemotherapy + ADC +/- EGFR ex20ins TKI Amivantamab EGFR ex20ins TKI + Amivantamab ADC +/- EGFR ex20ins TKI Chemotherapy Amivantamab + Chemotherapy +/- EGFR ADC +/- EGFR ex20ins TKI EGFR ex20ins TKI ??? ex20ins TKI

WU-KONG28 Study Design 202 ANN Sunvozertinib (300 mg, once daily, orally) Key Eligibility Criteria Cytologically/histogicall confirmed locally advanced or Randomized at 1:1 metastatic non-sq NSCLC Stratified by baseline Documented EGFR exon20ins brain metastasis (Y/N) Newly diagnosed or treatment naïve Platinum-based Chemotherapy ECOG: 0 or 1 (Carboplatin, AUC5 + pemetrexed, 500 Sunvozertinib PD mg/m2, Q3W up to 6 cycles, followed by (300 mg, once Primary Endpoint: pemetrexed maintenance therapy). daily, orally) PFS assessed by BICR a intravenous infusion Secondary Endpoints: OS (Key secondary) Crossover to sunvozertinib was allowed PFS assessed by investigator upon BICR-confirmed progressive disease ORR, DCR, DoR, and tumor size change Safety, Pharmacokinetics Exploratory Endpoints: PFS2 etc. for analysis: January 16, 2026; Abbreviation: AUC, Area Under Curve; BICR, Blinded Independent Central Non-small Review; Cell DCR, Lung Disease Cancer; Contral ORR, Objective Rate; DoR, Response Duration of Rate: Response; OS, Overall ECOG, Survival; Eastern PFS, Co- Data cut-off date primary EGFR, Epidermal Growth Factor Receptor; Exon20ins, Exon 20 Insertion Mutations; PFS2 is NSCLC, defined as the time from randomization to objective tumor progression on next line therapy based on operative Progression Oncology Free Survival; Group; PFS2, Second Progression Free Survival; QD, Once Daily; Q3W, Every 3 Weeks; I investigator Tumor assessment was conducted per RECIST 1.1 every 6 weeks in the first year and 12 weeks thereafter. assessment or death from any cause, whichever comes first. 4 0 OS follow-up was conducted every 3 months. ASCO - - PRESENTED BY: Dr. John V. Heymach, MD, PhD KNOWLEDGE CONQUERS CANCER ASCO #ASCO26 Presentation 5 property of the author and ASCO Permission required for revse, contact permissions@asong AL MEETING 2026ASCO ANNUAL MEETING ASCO ASCO --- Primary Endpoint: BICR-assessed PFS 202 ANN 100 Median Hazard Ratio P Value 90 (95% CI) (95% CI) 80 Sunvozertinib 10.3 (8.3, 14.0) 0.65 (0.50, 0.85) 0.0008 Chemotherapy 7.5 (6.7,8.5) Percentage of Patients 70 60 46.1% 50 33.2% 40 Sunvozertinib 30 26.7% 20 17.1% Chemotherapy 10 0 18 21 24 27 30 33 0 3 6 9 12 15 Months since Randomization Number At Risk: 26 18 9 3 0 48 34 74 60 108 7 6 2 1 0 Sunvozertinib 163 143 28 22 14 84 51 Chemotherapy 161 128 6 Median follow-up time: 24.0 months in the sunvozertinib arm and 18.0 months in the chemotherapy arm. KNOWLEDGE ASCO CONQUERS CANCER - CINCA $400,000 2026 ASCO #ASCO26 PRESENTED Presentation is property of the author and ASCO. Permission required for neuse, contact permissions@asce.org BT: Dr. John V. Heymach, MD, PhD AL MEETING 2026ASCO ASCO ANNUAL MEETING ASCO ASCO O --- BICR-assessed Tumor Response 2020 100 80 Sunvozertinib Armª Partial Response 100 ANN Stable Disease Partal Persponse Progressive Deease 80 Chemotherapy Arm State Doease 60 Not Evaluable Progressive Doease 60 Not Evaluable Best Tumor Change from Baseline (%) 40 40 20 20 0 0 -20 -20 40 40 -60 -60 -80 cORR: 58.9% -80 CORR: 31.1% Median tumor size shrinkage: 42.1% -100 -100 Median tumor size shrinkage: 24.7% Sunvozertinib (N=163) Chemotherapy (N=161) Best Objective Response Rate, % (95% CI) 68.1 (60.4,75.2) 35.4 (28.0,43,3) Confirmed Objective Response Rate, % (95% CI) 58.9(50.9,66.5) 31.1 (24.0, 38.8) Odds Ratio (95% CI); P value 3.2 (2.0, 5.0); P<0.0001 Disease Control Rate, % (95% CI) 94.5 (89.8,97.4) 85.7 (79.3,90.7) Calculated in patients with measurable target lesions at baseline assessed by BICR, including 158 patients in the sunvozertinib arm and 154 patients in the chemotherapy am. 8 2026 ASCO PRE SENTED BY: Dr. John V. Heymach, MD, PhD #ASCO26 ASCO CINICAL ONCOLOGY AL MEETING Presentation is property of the author and ASCO. Permission required for чи, contact permissions@asco org KNOWLEDGE CONQUERS CANCER --- Second Progression Free Survival (PFS2) 2026ASC ANNUAL MEET 100 Median Hazard Ratio P Value 90 (95% CI) (95% CI) 80 Sunvozertinib 21.7 (16.1, 24.3) 0.70 (0.52, 0.95) 0.0111 73.6% Chemotherapy 15.5 (13.4, 18.6) 70 Percentage of Patients 67.8% 60 55.8% First subsequent systemic therapy 50 Sunvozertinib arm 40 44.0% Sunvozertinib 46.6% (76/163) started subsequent therapy 30 72.4% (55/76) received chemotherapy 20 Chemotherapy Chemotherapy arm 10 72.0% (116/161) started subsequent therapy 0 91.4% (106ª/116) received sunvozertinib 0 3 6 9 12 15 18 21 24 27 30 33 36 (90.2% through in-study crossover) Months since Randomization Number At Risk: 157 142 116 95 77 60 49 31 16 11 2 0 Sunvozertinib 163 153 142 117 83 60 46 31 24 13 6 1 0 Chemotherapy 161 time: 23.6 months in the sunvozertinib arm and 24.1 months in the chemotherapy arm. Median follow-up defined as the time from the date of randomization to the time of second disease progression or death, whichever comes outside first, of after the the study first subsequent anti-cancer therapy. 10 PFS2 a Including is 101 patients (90.2%) who received sunvozertinib via in-study crossover and 5 patients who received sunvozertinib ASCO MOIOR CINCE INCOLOGY PRE SENTED BY: Dr. John V. Heymach, MD, PhD 2026 ASCO ENOWLEDGE CONQUERS CANCER #ASCO26 Presentation property of he author and ASCO. Permission required for reuse, contact permissions@asco.org AL MEETING 2026ASCO ANNUAL MEETING ASCO ASCO

O 2026 ASCO NG ANNUAL MEETING Sunvozertinib Monotherapy versus Platinum-based Chemotherapy as First-line Treatment for Advanced NSCLC with EGFR Exon20ins: Primary Analysis of A Multinational Phase 3 Randomized Study (WU-KONG28) John V. Heymach1, Geoffrey Liu², Ligang Xing³, Laurent Greiller', John Thomas⁵, Ozan Yazic/5, Meil Sun Yun Fan*, Chengzhi Zhou Mengzhao Wang Regan M Memmott Dariusz Kowalski¹, Catherine Shu¹³, Elaine Shum14, Elvire Pons-Tostivint Federica Bertolini Gonzalo Fernandez Hinojan Lorenzo Antonuzzo¹⁸, Yiman Wang", Calcun Zhou Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, the USA Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Radution Ononiogy, Shandong Cancer Hospital and institute, Jhan, China, "Department of Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique-Höpitaux de Marselle, Ax Marseile University, Marseille, France, Department of Medical Oncology, Peter MacCalium Cancer Centre, Melbourne, Australia; Department of Medical Oncology, Gazi University Hospital, Arkara, Turkey, Department of Oncology, Jinan Central Hospital, Shandong University, Jhan, China, Department of Thoracic Medical Oncology, Zhejang Cancer Hospital, Hangzhou, China; Department of Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, "Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China; "Department of Internal Medicine, The Ohio State University James Comprehensive Cancer Center, Columbus, OM, the USA Department USA; Division of Medical Oncology and Hematology, Perimuter Cancer Center, NYU Langone Health, New York, NY, the USA, "Department of Medical Oncology, Nantes University Hospital, Nantes, France of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research institute of Onoology, Warsaw, Poland, "Department of Medicine, Columbia University inving Medical Center, New York, NY, the "Division of Oncology, Department of Oncology and Hematology, Modena University Hospital, Modena, Italy, "Department of Medical Onoology, Clinica Universidad de Navama, Madrid, Spain; "Department of of Experimental and Clinical Medicine, University of Florence, and the Medical Oncology Unit Careggi University Hospital, Florence, italy, "Dizal (Jangsu) Pharmaceutical Co. Ltd. Shanghai, China POepartment Oncology, Shanghai Pulmonary Hospital; Shanghai East Hospital, Shanghai, China PAL SENTED BY: Dr. John V. Heymach, MD, PhD ASCO 2026 ASCO #ASCO26 KNOWLEDGE COMQUARA CANCER ANNUAL MEETING I importy author and ASCO Person 2026ASCO A ANNUAL MEETING A ASCO ASCO ASCO ASCO ASCO ASCO ASCO A ASCO ASCO ASCO ASCO ASCO ASCO ASCO A ASCO ASC ASCO ASCO ASCO ASCO --- CO Key Takeaways EETING EFFICACY SAFETY Sunvozertinib vs Chemotherapy Sunvozertinib WU-KONG28 met its primary endpoint: statistically significant Safety profile similar to previous and clinically meaningful PFS improvement with sunvozertinib reports and manageable Improved ORR and prolonged DoR with sunvozertinib No new safety signals 2 2026 ASCO ASCO26 PRESENTED BY Dr. John V. Heymach, MD, PhD ASCO ANNUAL MEETING - - - and ABOD - - - ENGWLEDGE CONDUERS CANCER 2026ASCO ANNUAL MEETING ASCO ASCO ASCO ASCO ASCO ASCO ASCO ASCO ASCO ASCO AS A ASCO ASCO ASCO ASCO ASCO

100 Median 90 Progression-free Survival 80 (95% CI) 70 mo Percentage of Patients 60 Sunvozertinib 10.3 (8.3-14.0) Chemotherapy 7.5 (6.7-8.5) 50 46.1 Hazard ratio for disease 40 33.2 progression or death, 30 0.65 (95% CI, 0.50-0.85) Sunvozertinib P<0.001 20 26.7 Chemotherapy 10 17.1 0 0 3 6 9 12 15 18 21 24 27 30 33 Months since Randomization No. at Risk Sunvozertinib 163 143 108 74 60 48 34 26 18 9 3 0 Chemotherapy 161 128 84 51 28 22 14 7 6 2 1 0

The NEW ENGLAND JOURNAL of MEDICINE ORIGINAL ARTICLE First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations Caicun Zhou,¹ L. Greillier,² G. Liu,³ T. John,⁴ L. Xing,⁵ D. Kowalski,6 R.M. Memmott,⁷ O. Yazici,⁸ M. Sun,⁹ C. Shu, 10 E. Pons-Tostivint, 11 Y. Fan, 12 G. Fernandez-Hinojal, 13 E. Shum,¹ 14 M. Wang, 15 F. Bertolini, 16 D.R. Camidge,¹⁷ Chengzhi Zhou, 18 L. Doucet, 19 Q. Hong, J. Fang,²¹ D. Huang, 22 B. Jin, Y. Yu, 24 L. Antonuzzo,²⁵ D. Moro-Sibilot, J. Bennouna, 27 G. de Castro, Jr., 28 L. Zheng,²⁹ and J.V. Heymach,30 for the WU-KONG28 Investigators* 100 Median 90 Progression-free Survival 80 (95% CI) 70 mo Percentage of Patients 60 Sunvozertinib 10.3 (8.3-14.0) Chemotherapy 7.5 (6.7-8.5) 50 46.1 Hazard ratio for disease 40 33.2 progression or death, 30 0.65 (95% CI, 0.50-0.85) Sunvozertinib P<0.001 20 26.7 Chemotherapy 10 17.1 0 0 3 6 9 12 15 18 21 24 27 30 33 Months since Randomization No. at Risk Sunvozertinib 163 143 108 74 60 48 34 26 18 9 3 0 Chemotherapy 161 128 84 51 28 22 14 7 6 2 1 0 Figure 1. Progression-free Survival. Shown are Kaplan-Meier estimates of progression-free survival as assessed by blinded independent central review in the efficacy population, which included all the patients who had undergone randomization. The tick marks indi- cate censoring of data.

WU-KONG28 Study Design Sunvozertinib (300 mg, once daily, orally) Key Eligibility Criteria Cytologically/histologically confirmed locally advanced or Randomized at 1:1 metastatic non-sq NSCLC Stratified by baseline Documented EGFR exon20ins brain metastasis (Y/N) Newly diagnosed or treatment naïve Platinum-based Chemotherapy ECOG: 0 or 1 (Carboplatin, AUC5 + pemetrexed, 500 Sunvozertinib PD mg/m2, Q3W up to 6 cycles, followed by (300 mg, once Primary Endpoint: pemetrexed maintenance therapy), daily, orally) PFS assessed by BICR a intravenous infusion Secondary Endpoints: OS (Key secondary) Crossover to sunvozertinib was allowed PFS assessed by investigator a upon BICR-confirmed progressive disease ORR, DCR, DoR, and tumor size change Safety, Pharmacokinetics Exploratory Endpoints: PFS2 etc. Data cut-off date for primary analysis: January 16, 2026; Abbreviation: AUC, Area Under Curve; BICR, Blinded Independent Central Review; DCR, Disease Contral Rate; DoR, Duration of Response; ECOG, Eastern Co- operative Oncology Group; EGFR, Epidermal Growth Factor Receptor; Exon20ins, Exon 20 Insertion Mutations; NSCLC, Non-small Cell Lung Cancer; ORR, Objective Response Rate; OS, Overall Survival; PFS, Progression Free Survival; PFS2, Second Progression Free Survival; QD, Once Daily; Q3W, Every 3 Weeks; PFS2 is defined as the time from randomization to objective tumor progression on next line therapy based on Investigator assessment or death from any cause, whichever comes first. a Tumor assessment was conducted per RECIST 1.1 every 6 weeks In the first year and 12 weeks thereafter. 4 b OS follow-up was conducted every 3 months. 2026 ASCO PRESENTED BY: Dr. John V. Heymach, MD, PhD #ASCO26 ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse; contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- Primary Endpoint: BICR-assessed PFS 100 Median Hazard Ratio P Value 90 (95% CI) (95% CI) 80 Sunvozertinib 10.3 (8.3, 14.0) 0.65 (0.50, 0.85) 0.0008 Percentage of Patients 70 Chemotherapy 7.5 (6.7, 8.5) 60 50 46.1% 40 33.2% 30 Sunvozertinib 20 26.7% 10 17.1% 0 Chemotherapy 0 3 6 9 12 15 18 21 24 27 30 33 Months since Randomization Number At Risk: Sunvozertinib 163 143 108 74 60 48 34 26 18 9 3 0 Chemotherapy 161 128 84 51 28 22 14 7 6 2 1 0 Median follow-up time: 24.0 months in the sunvozertinib arm and 18.0 months In the chemotherapy arm. 6 2026 ASCO PRESENTED BY: Dr. John V. Heymach, MD, PhD #ASCO26 ASCO AMERICAN SOCIETY OF ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.or CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER --- Subgroup Analysis of BICR-assessed PFS Subgroup No. of Events/Patients Hazard Ratio(95%CI) Sunvozertinib Chemotherapy Overall 111/163 115/161 0.65 (0.50, 0.85) Age Group <65 years 66/89 71/93 0.62 (0.44, 0.87) >65 years 45/74 44/68 0.71 (0.46, 1.07) Sex Female 54/87 70/105 0.68 (0.48, 0.97) Male 57/76 45/56 0.58 (0.39,0.85) Race Asian 77/102 79/102 0.56 (0.41, 0.77) Non-Asian 34/61 36/59 0.93 (0.58,1.48) Region North America EU 27/50 33/52 0.78 (0.47, 1.30) Others 84/113 82/109 0.62 (0.45,0.84) Smoking History Never 64/101 74/107 0.61 (0.43,0.85) Ever 47/62 41/54 0.73 (0.48,1.11) Baseline ECOG 0 28/46 26/43 0.77 (0.45,1.31) >1 83/117 89/118 0.62 (0.46,0.84) Brain Metastasis at Baseline With 14/21 12/20 0.96 (0.44, 2.08) Without 97/142 103/141 0.62 (0.47,0.83) EGFR Exon20ins Subtype 769 ASV 34/51 39/52 0.46 (0.29,0.73) 770_SVD 15/21 19/32 Other/Unknown 62/91 57/77 0.77 (0.53,1.10) EGFR Exon20ins Region Near loop 77/111 79/109 0.59(0.43,0.82) Far loop 28/41 30/43 0.83 (0.49, 1.38) C-helix/Unknown 6/11 6/9 Disease Related Surgery With 21/34 19/31 0.55 (0.29, 1.02) Without 90/129 96/130 0.69 (0.51,0.92) 0.2 1 2 4.5 Favors Sunvozertinib Favors Chemotherapy 7 2026 ASCO PRE SENTED BY: Dr. John V. Heymach, MD, PhD #ASCO26 ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse: contact permissions@asco.or KNOWLEDGE CONQUERS CANCER --- Interim Analysis of Overall Survival 100 Median 90 (95% CI) Sunvozertinib 29.8 (21.8, NE) 80 Chemotherapy 28.8 (20.7, NE) 70 Percentage of Patients 60 Sunvozertinib os data maturity 50 38.9% (126/324) 40 Chemotherapy 38.0% (62/163) in the sunvozertinib arm 30 39.8% (64/161) in the chemotherapy arm 20 In-study crossover 10 90.2% (101/112) patients with BICR- 0 confirmed progressive disease crossed 0 3 6 9 12 15 18 21 24 27 30 33 36 39 over to receive sunvozertinib treatment Months since Randomization Number At Risk: Sunvozertinib 163 158 149 132 108 92 76 67 60 40 21 8 2 0 Chemotherapy 161 154 147 134 113 97 79 62 55 40 24 10 2 0 Median follow-up time: 26.1 months in the sunvozertinib arm and 26.7 months in the chemotherapy arm. 11 2026 ASCO PRE SENTED BY: Dr. John V. Heymach, MD, PhD #ASCO26 ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

Primary Endpoint: BICR-assessed PFS 100 Median Hazard Ratio P Value 90 (95% CI) (95% CI) 80 Sunvozertinib 10.3 (8.3, 14.0) 0.65 (0.50, 0.85) 0.0008 Percentage of Patients 70 Chemotherapy 7.5 (6.7, 8.5) 60 50 46.1% 40 33.2% 30 Sunvozertinlb 20 26.7% 17.1% 10 Chemotherapy 0 0 3 6 9 12 15 18 21 24 27 30 33 Months since Randomization Number At Risk: Sunvozertinib 163 143 108 74 60 48 34 26 18 9 3 0 Chemotherapy 161 128 84 51 28 22 14 7 6 2 1 0 Median follow-up time: 24.0 months in the sunvozertinib arm and 18.0 months in the chemotherapy arm. 6 2026 ASCO PRE SENTED BY: Dr. John V. Heymach, MD, PhD #ASCO26 ASCO AMERICAN SOCIETY OF CUNICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org org. KNOWLEDGE CONQUERS CANCER --- BICR-assessed Tumor Response Partial Response 100 Stable Disease Partial Response Chemotherapy Armᵃ Progressive Disease 100 Stable Disease 80 Not Evaluable Sunvozertinib Armᵃ Progressive Disease 80 Not Evaluable 60 60 40 Best Tumor Change from Baseline (%) 40 20 20 0 0 -20 -20 -40 -40 -60 -60 cORR: 31.1% cORR: 58.9% -80 -80 Median tumor size shrinkage: 24.7% Median tumor size shrinkage: 42.1% -100 -100 Sunvozertinib (N=163) Chemotherapy (N=161) Best Objective Response Rate, % (95% CI) 68.1 (60.4, 75.2) 35.4 (28.0, 43.3) Confirmed Objective Response Rate, % (95% CI) 58.9 (50.9, 66.5) 31.1 (24.0, 38.8) Odds Ratio (95% CI); P value 3.2 (2.0, 5.0); P<0.0001 Disease Control Rate, % (95% CI) 94.5 (89.8, 97.4) 85.7 (79.3, 90.7) Calculated in patients with measurable target lesions at baseline assessed by BICR, including 158 patients in the sunvozertinib arm and 154 patients in the chemotherapy arm. 8 ASCO #ASCO26 PRE SENTED BT: Dr. John V. Heymach, MD, PhD ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY --- Second Progression Free Survival (PFS2) 100 Median Hazard Ratio P Value 90 (95% CI) (95% CI) 80 Sunvozertinib 21.7 (16.1, 24.3) 0.70 (0.52, 0.95) 0.0111 73.6% Chemotherapy 15.5 (13.4, 18.6) 70 Percentage of Patients 67.8% 60 55.8% First subsequent systemic therapy 50 Sunvozertinib arm 40 44.0% Sunvozertinib 46.6% (76/163) started subsequent therapy 30 72.4% (55/76) received chemotherapy 20 Chemotherapy Chemotherapy arm 10 72.0% (116/161) started subsequent therapy 0 0 3 6 9 12 15 18 21 24 27 30 33 36 91.4% (106a/116) received sunvozertinib (90.2% through in-study crossover) Months since Randomization Number At Risk: Sunvozertinib 163 157 142 116 95 77 60 49 31 16 11 2 0 Chemotherapy 161 153 142 117 83 60 46 31 24 13 6 1 0 Median follow-up time: 23.6 months in the sunvozertinib arm and 24.1 months in the chemotherapy arm. PFS2 is defined as the time from the date of randomization to the time of second disease progression or death, whichever comes first, after the first subsequent anti-cancer therapy. a Including 101 patients (90.2%) who received sunvozertinib via in-study crossover and 5 patients who received sunvozertinib outside of the study 10 2026 ASCO #ASCO26 PRESENTED BY: Dr. John V. Heymach, MD, PhD ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org. KNOWLEDGE CONQUERS CANCER --- Subsequent Treatment Sunvozertinib Arm Chemotherapy Arm 100 100 90 90 80 80 70 57.8 63.9 64.5 70 1 line 73.0 With 1 line 60 Discontinued 60 84.5 85.3 Patients (%) 50 Patients (%) Discontinued With 50 40 40 30 30 23.3 2 lines 25.0 20 36.1 2 lines 20 27.0 Without 10 Ongoing 10 15.5 10.5 14.7 19.0 Ongoing Without >3 lines 23 lines 0 0 Sunvozertinib Subsequent Therapy Lines of Subsequent Therapy Chemotherapy Subsequent Therapy Lines of Subsequent Therapy (N=163) (N=119) (N=76) (N=161) (N=136) (N=116) Types of subsequent therapies included amivantamab, antiangiogenic therapy, chemotherapy, immunotherapy, targeted therapy (e.g., sunvozertinib and other EGFR TKI) and Other 12 2026 ASCO #ASCO26 PRESENTED BY: Dr. John V. Heymach, MD, PhD ASCO AMERICAN SOCIETY OF ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org org. CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

Therapeutic advances in EGFR ex20 ins mutations EXCLAIM EXCLAIM-2 Accelerated approval Mobocertinib vs mobocertinib Chemo Structural basis PFS:9.6v9.6m resistance to 1G Tmi (months) EGFR TKI in Ex20 CHRYSALIS insertions Accelerated approval Roubichoux et al. WU-KONG 1B Yasuda STM 2013 - amivantamab Structural-functional Accelerated approval (monotherapy) basis classification Sunvozertinib 200 mg 2013 2015 2017 2019 2021 2023 2024 2025 2026 Yang et al. Role of Osimertinib 160 mg OM PAPILLON FAVOUR WU-KONG 28 afatinib in uncommon POSITION20 SoC chemo- Firmonertinib Phase III mutations (LUX-2, ORR 28% mPFS 6.8 m amivantamab ORR 78.6% Sunvozertinib 300 mg LUX-3, LUX-6) ECOG ACRIN EA5162 mDoR 15.2 m vs chemo - 3 cohorts: Exon 20 ins/atypicals/ T790M ORR 24%, mPFS 9.6 m Limited efficacy for / - afatinib in exon 20 ins 2026 ASCO #ASCO26 PRESENTED BY: Daniel SW Tan. National Cancer Centre Singapore ASCO AMERICAN SOCIETY O CUNICAL ONCOLOGY ANNUAL MEETING Presentation property of the author and ASCO Permission required for num KNOWLEDGE CONQUERS CANCER

WU-KONG28 Study Design Sunvozertinib Key Eligibility Criteria (300 mg, once daily, orally) Cytologically/histogicall confirmed locally advanced or Randomized at 1:1 metastatic non-sq NSCLC Stratified by baseline Documented EGFR exon20ins brain metastasis (Y/N) Newly diagnosed or treatment naive ECOG: 0 or 1 Platinum-based Chemotherapy (Carboplatin, AUC5 + pemetrexed, 500 Sunvozertinib PD mg/m2, Q3W up to 6 cycles, followed by Primary Endpoint: (300 mg, once PFS assessed by BICR a pemetrexed maintenance therapy). daily, orally) intravenous infusion Secondary Endpoints: OS (Key secondary) b Crossover to sunvozertinib was allowed PFS assessed by investigator ᵃ upon BICR-confirmed progressive disease ORR, DCR, DoR, and tumor size change Safety, Pharmacokinetics Exploratory Endpoints: PFS2 etc. Data cut-off date for primary analysis: January 16, 2026; Abbreviation: AUC, Area Under Curve; BICR, Blinded Independent Central Review; DCR, Disease Contral Rate; DoR, Duration of Response; ECOG, Eastern Co- operative Oncology Group; EGFR, Epidermal Growth Factor Receptor; Exon20ins, Exon 20 Insertion Mutations; NSCLC, Non-small Cell Lung Cancer; ORR, Objective Response Rate; os, Overall Survival; PFS, Progression Free Survival; PFS2, Second Progression Free Survival; QD, Once Daily; Q3W, Every 3 Weeks; PFS2 is defined as the time from randomization to objective tumor progression on next line therapy based on investigator assessment or death from any cause, whichever comes first. a Tumor assessment was conducted per RECIST 1.1 every 6 weeks in the first year and 12 weeks thereafter. b OS follow-up was conducted every 3 months. PRESENTED BY: Dr. John V. Heymach, MD, PhD ASCO AMERICAN CUNICAL 2026 ASCO #ASCO26 KNOWLEDGE CONQUERS NNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org --- Second Progression Free Survival (PFS2) 100 Median Hazard Ratio P Value 90 (95% CI) (95% CI) 80 Sunvozertinib 21.7 (16.1, 24.3) 0.70 (0.52, 0.95) 0.0111 73.6% Chemotherapy 15.5 (13.4, 18.6) 70 Percentage of Patients 67.8% 60 55.8% First subsequent systemic therapy 50 Sunvozertinib arm 40 44.0% Sunvozertinib 46.6% (76/163) started subsequent therapy 30 72.4% (55/76) received chemotherapy 20 Chemotherapy Chemotherapy arm 10 72.0% (116/161) started subsequent therapy 0 9 12 15 18 21 24 27 30 33 36 91.4% (106a/116) received sunvozertinib 0 3 6 (90.2% through in-study crossover) Months since Randomization Number At Risk: Sunvozertinib 163 157 142 116 95 77 60 49 31 16 11 2 0 Chemotherapy 161 153 142 117 83 60 46 31 24 13 6 1 0 Median follow-up time: 23.6 months in the sunvozertinib arm and 24.1 months in the chemotherapy arm. PFS2 is defined as the time from the date of randomization to the time of second disease progression or death, whichever comes first, after the first subsequent anti-cancer therapy 10 a Including 101 patients (90.2%) who received sunvozertinib via in-study crossover and 5 patients who received sunvozertinib outside of the study 2026 ASCO PRESENTED BY: Dr. John V. Heymach, MD, PhD ASCO AMERICAN SOCIETY of CUMICAL OHCOLOGY #ASCO26 ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org. KNOWLEDGE CONQUERS CANCER --- Overview of Safety Sunvozertinib Chemotherapy (N=163)ᵃ (N=150)ᵃ Participants with Any TRAE 163 (100.0) 146 (97.3) Any TRAE with Grade ≥3 100 (61.3) 74 (49.3) Any Treatment-related SAE 30 (18.4) 19 (12.7) Any TRAE Leading to Dose Interruption 74 (45.4) 41 (27.3) Any TRAE Leading to Dose Reduction 66 (40.5) 36 (24.0) Any TRAE Leading to Treatment Discontinuation 12 (7.4) 17 (11.3) Any TRAE with Fatal Outcome 0 (0.0) 1 (0.7)b In the sunvozertinib arm, the top TRAEs leading to dose interruption and reduction included blood CPK increased and diarrhea, which did not lead to treatment discontinuation. Abbreviation: SAE, Serious Adverse Event; TRAE, Treatment-related Adverse Event. TRAEs included any events considered as related to the randomized treatment. a only included patients who received randomized treatment; b The drug-related TEAE with fatal outcome in the chemotherapy arm was pneumonia. 13 2026 ASCO #ASCO26 PRESENTED BY: Dr. John V. Heymach, MD, PhD ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org ASCO AMERICAN GOCETY OF CLINICAL CHICOLOGE KNOWLEDGE CONQUERS CANCER

Overview of Safety Sunvozertinib Chemotherapy (N=163)ᵃ (N=150)a Participants with Any TRAE 163 (100.0) 146 (97.3) Any TRAE with Grade ≥3 100 (61.3) 74 (49.3) Any Treatment-related SAE 30 (18.4) 19 (12.7) Any TRAE Leading to Dose Interruption 74 (45.4) 41 (27.3) Any TRAE Leading to Dose Reduction 66 (40.5) 36 (24.0) Any TRAE Leading to Treatment Discontinuation 12 (7.4) 17 (11.3) Any TRAE with Fatal Outcome 0 (0.0) 1 (0.7)b In the sunvozertinib arm, the top TRAEs leading to dose interruption and reduction included blood CPK increased and diarrhea, which did not lead to treatment discontinuation. Abbreviation: SAE, Serious Adverse Event; TRAE, Treatment-related Adverse Event. TRAEs included any events considered as related to the randomized treatment. 13 a only included patients who received randomized treatment; b The drug-related TEAE with fatal outcome in the chemotherapy arm was pneumonia. 2026 ASCO #ASCO26 PRESENTED BY: Dr. John V. Heymach, MD, PhD ASCO AMERICAN SOCIETY OF CUNICAL ONCOLOGY ANNUAL MEETING Presentation KNOWL EDGE CONQUERS ANCER --- Common Treatment-related Adverse Events (≥ 20%) Sunvozertinib (N=163) Chemotherapy (N=150) All Grade ≥ Grade 3 All Grade ≥ Grade 3 Participants with Any TRAE 163 (100.0) 100 (61.3) 146 (97.3) 74 (49.3) Diarrhea 137 (84.0) 22 (13.5) 15 (10.0) 0 (0.0) Blood creatine phosphokinase increased 90 (55.2) 33 (20.2) 5 (3.3) 1 (0.7) Rash 84 (51.5) 1 (0.6) 8 (5.3) 0 (0.0) Paronychia 79 (48.5) 6 (3.7) 0 (0.0) 0 (0.0) Anemia 75 (46.0) 10 (6.1) 91 (60.7) 15 (10.0) Weight decreased 56 (34.4) 5 (3.1) 15 (10.0) 1 (0.7) Decreased appetite 52 (31.9) 1 (0.6) 39 (26.0) 2 (1.3) Blood creatinine increased 50 (30.7) 1 (0.6) 12 (8.0) 0 (0.0) Vomiting 40 (24.5) 3 (1.8) 32 (21.3) 3 (2.0) Nausea 38 (23.3) 3 (1.8) 66 (44.0) 2 (1.3) Aspartate aminotransferase increased 35 (21.5) 3 (1.8) 52 (34.7) 1 (0.7) Lipase increased 35 (21.5) 9 (5.5) 8 (5.3) 1 (0.7) Amylase increased 34 (20.9) 2 (1.2) 11 (7.3) 0 (0.0) Alanine aminotransferase increased 25 (15.3) 2 (1.2) 50 (33.3) 2 (1.3) Neutrophil count decreased 22 (13.5) 4 (2.5) 68 (45.3) 28 (18.7) White blood cell count decreased 20 (12.3) 1 (0.6) 58 (38.7) 10 (6.7) Platelet count decreased 11 (6.7) 2 (1.2) 32 (21.3) 10 (6.7) Constipation 4 (2.5) 0 (0.0) 30 (20.0) 0 (0.0) 14 2026 ASCO #ASCO26 PRESENTED BY: Dr. John V. Heymach, MD, PhD ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- Conclusion In the primary analysis of WU-KONG28 study, sunvozertinib demonstrated significantly superior anti- tumor efficacy than platinum-containing chemo doublet in 1L advanced NSCLC patients with EGFR exon20ins: Statistically significant and clinically meaningful improvement in PFS (mPFS: 10.3 VS 7.5 months; HR: 0.65; P=0.0008) Higher ORR (58.9% VS 31.1%) and DCR (94.5% VS 85.7%), and longer DoR (11.2 VS 7.1 months) The OS data were immature (38.9% maturity). The PFS2 suggested a long-term survival benefit with sunvozertinib (21.7 months VS 15.5 months) The common TRAEs of sunvozertinib were related to wild-type EGFR inhibition and clinically manageable These results support sunvozertinib as first-line treatment for NSCLC patients with EGFR exon20ins, with the advantage of a single oral agent 15 2026 ASCO PRESENTED BY: Dr. John V. Heymach, MD, PhD ASCO AMERICAN SOCIETY OF #ASCO26 CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissiona@asco.org KNOWLEDGE CONQUERS CANCER

Interim Analysis of Overall Survival 100 Median 90 (95% CI) Sunvozertinib 29.8 (21.8, NE) 80 Chemotherapy 28.8 (20.7, NE) 70 Percentage of Patients 60 Sunvozertinib OS data maturity 50 38.9% (126/324) 40 Chemotherapy 38.0% (62/163) in the sunvozertinib arm 30 39.8% (64/161) in the chemotherapy arm 20 In-study crossover 10 90.2% (101/112) patients with BICR- 0 confirmed progressive disease crossed 0 3 6 9 12 15 18 21 24 27 30 33 36 39 over to receive sunvozertinib treatment Months since Randomization Number At Risk: Sunvozerfinib 163 158 149 132 106 92 76 67 60 40 21 a 2 0 Chemotherapy 161 154 147 134 113 97 TO 62 55 40 24 10 2 0 Median follow-up time 26.1 months in the sunvozertinib arm and 26.7 months in the chemotherapy arm. 11 2026 ASCO #ASCO26 PRE SENTED BY: Dr. John V. Heymach, MD, PhD ASCO - OF CLARKEAL - ANNUAL MEETING Possentation - property of - - and ACCO Person required - - contact - KNOWLEDGE CONQUERS CANCER --- Subsequent Treatment Sunvozertinib Arm Chemotherapy Arm 100 100 90 90 80 80 57.8 70 63.9 64.5 70 1 line 73.0 With 1 line 60 Discontinued 60 84.5 85.3 Patients (%) Patients (%) Discontinued With 50 50 40 40 23.3 30 30 2 lines 25.0 20 36.1 2 lines 20 27.0 Without 10 Ongoing 10 19.0 15.5 14.7 10.5 Ongoing 23 lines Without >3 lines 0 0 Sunvozertinib Subsequent Therapy Lines of Subsequent Therapy Chemotherapy Subsequent Therapy Lines of Subsequent Therapy (N=163) (N=119) (N=76) (N=161) (N=136) (N=116) Types of subsequent therapies included amivantamab, antiangiogenic therapy, chemotherapy, immunotherapy, targeted therapy (e.g., sunvozertinib and other EGFR TKI) and Other 12 2026 ASCO #ASCO26 PRESENTED BY: Dr. John V. Heymach, MD, PhD ASCO AMERICAN SOCH CUNICAL ONCOL